2026-04-28T22:57:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/179772024-11-28T14:53:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Calleja-Panero, José Luis author Andrade, Raúl J. author Bañares, Rafael author Crespo, Javier author Esteban, Rafael author Jarque, Isidro author Mingot-Castellano, María Eva author Romero-Gómez, Manuel author Muñoz-Peñín, Rocío author Bentley, Roy author Shepherd, John author Gil, Alicia author 2020 Background: chronic liver disease (CLD) patients often present thrombocytopenia (TCP) and when severe, it may prevent them from undergoing necessary invasive procedures due to an increased bleeding risk. The lack of scientific evidence makes it impossible to determine key aspects of the current management and associated healthcare burden of these patients in Spain. Purpose: to gain insight into the current situation of patients with CLD-associated severe TCP undergoing invasive procedures in Spain, based on the experience of clinical experts. Methods: national Delphi study involving 32 medical experts. Results: the estimated prevalence of CLD-associated severe TCP is approximately 5,967, with an annual incidence of 1,148 new patients. Patients undergo a median of 1 (0-3) invasive procedures/year. Platelet transfusions (PTs) are the standard option to raise platelet counts and are associated with significant burden. The achievement of target platelet levels (≥ 50 x 109/l) after a transfusion is not routinely measured. The lack of effectiveness and short life span of transfused platelets can lead to procedure cancellations and bleeding events, which potentially affect patient outcomes. Adverse events occur in 1-25 % of patients, including mild (febrile and allergic reactions) and severe events (e.g., transfusion-related acute lung injury). Between 5-15 % of patients are unfit to receive PTs and approximately 3 % are treated off-label with thrombopoietin receptor agonists. Conclusions: this study provides a snapshot of the current situation in Spain, highlighting that the current management is poorly standardized and suboptimal in some cases. The results suggest the benefit of developing a consensus document to address some of these shortcomings and to advance in the search for alternatives to PTs. 1130-0108 http://hdl.handle.net/10668/3490 http://hdl.handle.net/20.500.12105/17977 32954777 10.17235/reed.2020.6895/2020 2340-4167 Revista Española de Enfermedades Digestivas Thrombocytopenia Chronic liver disease Platelet transfusion Delphi Epidemiology Treatment Thrombopoietin receptor agonists Trombocitopenia Transfusión de plaquetas Técnica Delfos Epidemiología Terapéutica Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts